{"title":"Absolute retinal blood flow in healthy eyes and in eyes with retinal vein occlusion","authors":"Thibaud Mautuit , Pierre Cunnac , Frédéric Truffer , André Anjos , Rebecca Dufrane , Gilbert Maître , Martial Geiser , Christophe Chiquet","doi":"10.1016/j.mvr.2023.104648","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To measure non-invasively retinal venous blood flow<span> (RBF) in healthy subjects and patients with retinal venous occlusion (RVO).</span></p></div><div><h3>Methods</h3><p>The prototype named AO-LDV (Adaptive Optics Laser Doppler Velocimeter), which combines a new absolute laser Doppler velocimeter with an adaptive optics fundus<span><span> camera (rtx1, Imagine Eyes®, Orsay, France), was studied for the measurement of absolute RBF as a function of retinal vessel diameters and simultaneous measurement of </span>red blood cell velocity. RBF was measured in healthy subjects (n = 15) and patients with retinal venous occlusion (RVO, n = 6). We also evaluated two softwares for the measurement of retinal vessel diameters: software 1 (automatic vessel detection, profile analysis) and software 2 (based on the use of deep neural networks for semantic segmentation of vessels, using a M2u-Net architecture).</span></p></div><div><h3>Results</h3><p>Software 2 provided a higher rate of automatic retinal vessel measurement (99.5 % of 12,320 AO images) than software 1 (64.9 %) and wider measurements (75.5 ± 15.7 μm vs 70.9 ± 19.8 μm, <em>p</em> < 0.001). For healthy subjects (n = 15), all the retinal veins in one eye were measured to obtain the total RBF. In healthy subjects, the total RBF was 37.8 ± 6.8 μl/min. There was a significant linear correlation between retinal vessel diameter and maximal velocity (slope = 0.1016; <em>p</em> < 0.001; <em>r</em><sup>2</sup> = 0.8597) and a significant power curve correlation between retinal vessel diameter and blood flow (3.63 × 10<sup>−5</sup> × D<sup>2.54</sup>; <em>p</em> < 0.001; <em>r</em><sup>2</sup><span><span> = 0.7287). No significant relationship was found between total RBF and systolic and diastolic blood pressure, ocular perfusion pressure, heart rate, or hematocrit. For RVO patients (n = 6), a significant decrease in RBF was noted in occluded veins (3.51 ± 2.25 μl/min) compared with the </span>contralateral healthy eye (11.07 ± 4.53 μl/min). For occluded vessels, the slope between diameter and velocity was 0.0195 (</span><em>p</em> < 0.001; <em>r</em><sup>2</sup> = 0.6068) and the relation between diameter and flow was Q = 9.91 × 10<sup>−6</sup> × D<sup>2.41</sup> (<em>p</em> < 0.01; <em>r</em><sup>2</sup> = 0.2526).</p></div><div><h3>Conclusion</h3><p><span>This AO-LDV prototype offers new opportunity to study RBF in humans and to evaluate treatment in retinal </span>vein diseases.</p></div>","PeriodicalId":18534,"journal":{"name":"Microvascular research","volume":"152 ","pages":"Article 104648"},"PeriodicalIF":2.9000,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microvascular research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0026286223001747","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
To measure non-invasively retinal venous blood flow (RBF) in healthy subjects and patients with retinal venous occlusion (RVO).
Methods
The prototype named AO-LDV (Adaptive Optics Laser Doppler Velocimeter), which combines a new absolute laser Doppler velocimeter with an adaptive optics fundus camera (rtx1, Imagine Eyes®, Orsay, France), was studied for the measurement of absolute RBF as a function of retinal vessel diameters and simultaneous measurement of red blood cell velocity. RBF was measured in healthy subjects (n = 15) and patients with retinal venous occlusion (RVO, n = 6). We also evaluated two softwares for the measurement of retinal vessel diameters: software 1 (automatic vessel detection, profile analysis) and software 2 (based on the use of deep neural networks for semantic segmentation of vessels, using a M2u-Net architecture).
Results
Software 2 provided a higher rate of automatic retinal vessel measurement (99.5 % of 12,320 AO images) than software 1 (64.9 %) and wider measurements (75.5 ± 15.7 μm vs 70.9 ± 19.8 μm, p < 0.001). For healthy subjects (n = 15), all the retinal veins in one eye were measured to obtain the total RBF. In healthy subjects, the total RBF was 37.8 ± 6.8 μl/min. There was a significant linear correlation between retinal vessel diameter and maximal velocity (slope = 0.1016; p < 0.001; r2 = 0.8597) and a significant power curve correlation between retinal vessel diameter and blood flow (3.63 × 10−5 × D2.54; p < 0.001; r2 = 0.7287). No significant relationship was found between total RBF and systolic and diastolic blood pressure, ocular perfusion pressure, heart rate, or hematocrit. For RVO patients (n = 6), a significant decrease in RBF was noted in occluded veins (3.51 ± 2.25 μl/min) compared with the contralateral healthy eye (11.07 ± 4.53 μl/min). For occluded vessels, the slope between diameter and velocity was 0.0195 (p < 0.001; r2 = 0.6068) and the relation between diameter and flow was Q = 9.91 × 10−6 × D2.41 (p < 0.01; r2 = 0.2526).
Conclusion
This AO-LDV prototype offers new opportunity to study RBF in humans and to evaluate treatment in retinal vein diseases.
期刊介绍:
Microvascular Research is dedicated to the dissemination of fundamental information related to the microvascular field. Full-length articles presenting the results of original research and brief communications are featured.
Research Areas include:
• Angiogenesis
• Biochemistry
• Bioengineering
• Biomathematics
• Biophysics
• Cancer
• Circulatory homeostasis
• Comparative physiology
• Drug delivery
• Neuropharmacology
• Microvascular pathology
• Rheology
• Tissue Engineering.